Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3

BackgroundClinical progression of Alzheimer’s disease is characterized by impairment in cognition and function.ObjectiveTo assess the relationship between cognitive and functional impairment in mild Alzheimer’s disease.DesignSpearman’s rank correlations between cognitive and functional measures were calculated. Autoregressive cross-lagged panel analyses were used to determine the temporal relationship between cognitive and functional decline.SettingPost-hoc analysis of clinical trial data.ParticipantsPlacebo-treated patients with mild Alzheimer’s disease from the Phase 3 solanezumab study EXPEDITION 3.InterventionPlacebo.MeasurementsCognitive and functional measures were assessed at baseline and at six post-baseline time points through Week 80.ResultsCorrelation between cognitive and functional measures was 0.41 at baseline and 0.65 at Week 80. Autoregressive cross-lagged panel analysis demonstrated that cognitive impairment preceded and predicted subsequent functional decline, but functional scores did not predict cognitive outcomes.ConclusionsThis study supports the hypothesis that functional impairment predictably follows cognitive decline in mild Alzheimer’s disease dementia.

[1]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[2]  Roy W Jones,et al.  On the path to 2025: understanding the Alzheimer’s disease continuum , 2017, Alzheimer's Research & Therapy.

[3]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[4]  E. Siemers,et al.  Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.

[5]  Karen L. Price,et al.  Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. , 2014, Journal of Alzheimer's disease : JAD.

[6]  E. Siemers,et al.  COGNITIVE IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.

[7]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[8]  Y. Stern,et al.  Cognitive Declines Precede and Predict Functional Declines in Aging and Alzheimer’s Disease , 2013, PloS one.

[9]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[10]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[11]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[12]  R. Petersen,et al.  Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.

[13]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.